Daily Respiratory Research Analysis
Three impactful respiratory studies stood out: an AI-enabled radiomic trajectory (RadioTrace) quantifies early-stage lung adenocarcinoma progression and predicts outcomes; a phase 2 trial shows andamertinib efficacy in EGFR exon 20 insertion-mutant NSCLC after prior therapy; and a first-in-human bronchoscopic balloon dilatation technique improves access to small peripheral lung lesions with promising diagnostic sensitivity.
Summary
Three impactful respiratory studies stood out: an AI-enabled radiomic trajectory (RadioTrace) quantifies early-stage lung adenocarcinoma progression and predicts outcomes; a phase 2 trial shows andamertinib efficacy in EGFR exon 20 insertion-mutant NSCLC after prior therapy; and a first-in-human bronchoscopic balloon dilatation technique improves access to small peripheral lung lesions with promising diagnostic sensitivity.
Research Themes
- AI-driven imaging biomarkers for lung cancer prognosis
- Targeted therapy in EGFR exon 20 insertion NSCLC
- Procedural innovation to improve bronchoscopy yield for small PPLs
Selected Articles
1. Quantifying Early-Stage Lung Adenocarcinoma Progression with a Radiomic Trajectory.
RadioTrace, a deep contrastive learning framework integrating radiomics and pathology, generated a continuous trajectory capturing progression of early-stage lung adenocarcinoma. It predicted STAS, nodal metastasis, and survival across four cohorts, revealing survival heterogeneity within the same pathological grade and aligning with progression-related genomic/transcriptomic features.
Impact: Provides an interpretable, quantitative biomarker that augments histopathology for risk stratification in early-stage lung adenocarcinoma, potentially informing adjuvant therapy and surveillance decisions.
Clinical Implications: May guide personalized adjuvant therapy and follow-up intensity by identifying high-risk biology within the same histologic grade; could standardize progression assessment across centers.
Key Findings
- Developed RadioTrace, a radiomic–pathology deep contrastive model that learns a continuous progression trajectory in esLUAD.
- Across four cohorts, the trajectory predicted STAS and lymph node metastasis and served as an independent prognostic factor (p < 0.004).
- Within the same pathological grade, the trajectory stratified patients into survival-distinct subgroups and correlated with progression-related molecular features; longitudinal CT series supported its temporal consistency.
Methodological Strengths
- Multi-institutional validation across four cohorts with consistent prognostic performance
- Integration of radiomics with pathology and multi-omic correlates; survival analyses and longitudinal consistency checks
Limitations
- Predominantly retrospective datasets; potential scanner/protocol heterogeneity
- Clinical utility not yet tested in prospective decision-impact or interventional studies
Future Directions: Prospective, multi-center decision-impact trials integrating RadioTrace into tumor boards; harmonization across imaging protocols and integration with liquid biopsy for composite risk scores.
Determining tumor progression status is critical for early-stage lung adenocarcinoma (esLUAD) diagnosis and treatment, yet histopathology-based grading often overlooks heterogeneity within grades. We propose RadioTrace, a deep contrastive learning framework integrating radiomic and pathological information to learn a radiomic trajectory for quantifying esLUAD progression. Across four multi-institutional cohorts, RadioTrace well predicted tumor phenotypes including spread through air spaces
2. Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study.
In 92 pretreated EGFR ex20ins NSCLC patients, andamertinib 240 mg QD yielded a confirmed ORR of 42.7% with median DOR 8.7 months and median PFS 6.2 months; 12-month OS rate was 70.5%, and activity extended to patients with brain metastases (systemic ORR 47.4%). Toxicities were manageable with grade ≥3 diarrhea (12.0%) and rash (7.6%); no ILD signals or significant QT prolongation were observed.
Impact: Delivers a potentially practice-informing option for a difficult-to-treat EGFR exon 20 insertion population with meaningful activity and manageable toxicity in a multicenter setting.
Clinical Implications: Supports consideration of andamertinib as a post-platinum/post-immunotherapy option for EGFR exon 20 insertion NSCLC, including patients with brain metastasis; comparative effectiveness vs. approved agents warrants further head-to-head trials.
Key Findings
- Confirmed ORR 42.7% (95% CI 32.4–53.0) with median DOR 8.7 months and median PFS 6.2 months after prior platinum or immunotherapy.
- Systemic confirmed ORR of 47.4% in patients with brain metastases, indicating intracranial-relevant activity.
- Manageable safety: grade ≥3 diarrhea (12.0%), rash (7.6%); no ILD or significant QTc issues reported.
Methodological Strengths
- Multicenter prospective phase 2 with independent response review
- Broad inclusion of nearly 30 EGFR exon 20 insertion subtypes
Limitations
- Single-arm design without comparator limits definitive efficacy attribution
- Overall survival not yet mature; external validity to earlier lines untested
Future Directions: Randomized head-to-head trials versus existing exon 20 insertion therapies; intracranial efficacy characterization and biomarker analyses for response/resistance.
OBJECTIVES: This study aimed to evaluate andamertinib, a selective and irreversible tyrosine kinase inhibitor, in pretreated advanced EGFR exon 20 insertion (ex20ins)-mutant NSCLC. METHODS: In the phase 2, multicenter, single-arm KANNON study (NCT06015503), patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations who had progressed after platinum-based chemotherapy or immunotherapy received oral andamertinib 240 mg once daily in 28-day cycles. The primary end point was the confirmed
3. Balloon dilatation for bronchoscope delivery: first-in-human trial of a novel technique for peripheral lung field access.
In 22 patients with bronchus sign-positive PPLs <20 mm, BDBD advanced the bronchoscope by an average of 2.3 bifurcations and enabled direct visualization of the biopsy site in 17/18 cancer cases. Under predefined procedural criteria, sensitivity for malignancy was 77.8% (14/18) with no serious adverse events. The technique appears feasible and safe, improving peripheral access.
Impact: Introduces a practical, generalizable technique to overcome airway caliber limitations and enhance diagnostic yield for small peripheral nodules—a major unmet need in interventional pulmonology.
Clinical Implications: BDBD could be integrated with existing navigation/ultrathin bronchoscopy workflows to improve diagnostic sensitivity for small PPLs while maintaining safety; requires training and standardized protocols.
Key Findings
- BDBD advanced bronchoscope by a mean 2.3 airway bifurcations toward PPLs <20 mm.
- Met procedural criteria in 18 cancer cases with 77.8% diagnostic sensitivity for malignancy and no serious adverse events.
- Direct visualization of biopsy site achieved in 17/18 cancer cases, supporting feasibility.
Methodological Strengths
- Prospective multicenter first-in-human evaluation with predefined procedural criteria
- Objective endpoints including scope advancement (bifurcations) and direct visualization
Limitations
- Single-arm small sample limits generalizability and comparative performance assessment
- Short-term evaluation without long-term safety or learning-curve analysis
Future Directions: Randomized or matched comparative studies versus standard ultrathin/navigation bronchoscopy; evaluation across various bronchus sign patterns, lesion sizes, and operator experience; cost-effectiveness analyses.
BACKGROUND: Bronchoscopic limitations in reaching peripheral pulmonary lesions (PPLs) can compromise biopsy sensitivity, especially for small PPLs. Therefore, we developed the balloon dilatation for bronchoscope delivery (BDBD) technique to dilate bronchial pathways and facilitate bronchoscope advancement into the periphery. This study evaluated the diagnostic performance and safety profile of transbronchial biopsy using this technique. METHODS: This multicentre, single-arm, prospective study included patients with